Professor Marc de Smet Senior Medical Advisor

Marc is Oxular’s Senior Medical Advisor and a practicing vitreoretinal surgeon, with more than 30 years of experience in ophthalmic drug and medical device development. Previously, he was the National Eye Institute’s representative responsible for defining the clinical trial of Foscarnet, the first approved drug to treat CMV retinitis in AIDS patients. He initiated the use of Methotrexate for the treatment of intraocular lymphoma and intraocular tuberculosis. In collaboration with Thrombogenics, he was responsible for preclinical and clinical activities of Ocriplasmin, leading to the commercialization of Jetrea. Marc also participated in the launch of OTI’s transversal retinal OCT imaging, and the development of Preceyes BV’s tele-operated eye surgery robot.

Scroll to Top